Status:
COMPLETED
Development and Validation of a Deep Learning-Based Survival Prediction Model for Pediatric Glioma Patients: A Retrospective Study Using the SEER Database and Chinese Data
Lead Sponsor:
Tang-Du Hospital
Conditions:
Glioma
Eligibility:
All Genders
Up to 21 years
Brief Summary
Accurately predicting the survival of pediatric glioma patients is crucial for informed clinical decision-making and selecting appropriate treatment strategies. However, there is a lack of prognostic ...
Detailed Description
This retrospective study focuses on survival prediction in pediatric glioma patients using a population-based approach. The model was trained using the Surveillance, Epidemiology, and End Results (SEE...
Eligibility Criteria
Inclusion
- To identify specific tumor types, the International Classification of Diseases for Oncology, 3rd Edition codes (ICD-O-3) were used, including codes 9450, 9394, 9421, 9384, 9383, 9424, 9400, 9420, 9410, 9411, 9380, 9382, 9391, 9393, 9390, 9401, 9381, 9451, 9440, 9441, 9442, 9430, and 9380, covering astrocytic tumors, oligodendroglia tumors, oligoastrocytic tumors, ependymal tumors, and other gliomas. Inclusion criteria comprised all primary brain tumors (C71.0-C71.9, C72.3, C72.8, C75.3) diagnosed, among patients under 21 years old, and meeting the third edition of the ICD-O-3 classification.
Exclusion
- Only patients with available survival time were included, and those with unknown or missing clinical features were excluded.
Key Trial Info
Start Date :
September 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 20 2023
Estimated Enrollment :
9532 Patients enrolled
Trial Details
Trial ID
NCT06199388
Start Date
September 20 2022
End Date
December 20 2023
Last Update
January 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tangdu Hospital
Xi'an, Shannxi, China, 710000